STX7

Across TCGA pan-cancer cohorts, STX7 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated STX7 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STX7 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated STX7 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where STX7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.886	.002	27	view →
LUAD	DFS	Quartile	II,III,IV	0.773	1.000	.009	8	view →
PDAC	OS	Median	IV	0.937	0.395	.026	3	view →
GBM	DFS	Quartile	All	0.874	0.656	.046	2	view →
HNSC	OS	Quartile	IV	0.522	0.781	.028	2	view →
LSCC	DFS	Quartile	III,IV	0.532	1.000	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

STX7–CCRCC (OS)

Open the CCRCC breakdown →